Results 31 to 40 of about 21,749 (235)
Romanian Journal of Cardiology, 2022 Our goal was to characterize a cohort of heart failure patients with and without COVID-19 in terms of demographics, comorbid conditions, treatment regimens, lab test results and outcome.
Vintilă Ana-Maria +9 more
doaj +1 more source
Brazilian Journal of Medical and Biological ResearchHeart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have symptoms and signs of HF with normal or near-normal left ventricular ejection fraction (LVEF ≥50%).
Chao Ma +4 more
doaj +1 more source
Reviews in Cardiovascular Medicine, 2022 Acute decompensated heart failure (ADHF) is one of the most common causes of hospital admission for cardiovascular diseases. ADHF often affects the elderly population, is associated with high morbidity, admission rate and mortality. Pulmonary congestion (
Hui Zhang +3 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu +3 more
wiley +1 more source
Clinical and Experimental Hypertension, 2019 Background: Resistant hypertension (RHT) is defined as high blood pressure despite three antihypertensive medications one being a diuretic. RHT is a common clinical problem and as a subgroup has not been studied widely. The present study has investigated
Ebru Ipek Turkoglu +1 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Patient Preference and Adherence, 2023 Chi Nguyen,1 Luke Bamber,2 Vincent J Willey,1 Thomas Evers,2 Thomas P Power,3 Judith J Stephenson1 1HealthCore, Inc., Wilmington, DE, USA; 2Bayer AG, Wuppertal, 42096, Germany; 3AIM Specialty Health, Chicago, IL, USACorrespondence: Chi Nguyen, HealthCore,
Nguyen C +5 more
doaj
Development and Challenges of Pre-Heart Failure with Preserved Ejection Fraction
Reviews in Cardiovascular Medicine, 2023 Pre-heart failure with preserved ejection fraction (Pre-HFpEF) is a critical link to the development of heart failure with preserved ejection fraction (HFpEF). Early recognition and early intervention of pre-HFpEF will halt the progression of HFpEF. This
Guoju Dong
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen +4 more
wiley +1 more source